Credit rating agency, CARE has reaffirmed ‘AAA’ rating to Cipla’s long term fund based bank facilities worth RS 60.09 crore. The rating agency has assigned ‘AAA’ rating to short term fund based bank facilities of the bank, while reaffirmed ‘A1+’ rating to the bank’s short term non fund based bank facilities worth Rs 58.41 crore.
The reaffirmation of ratings assigned to bank facilities of Cipla derives strength from its reputed brand having global presence, well established and experienced promoters, dominant market position in domestic pharmaceutical industry, robust operational performance and strong financial risk profile.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: